Three Portfolio Companies of Origin Ventures – SaneGene Bio, Excalipoint Biosciences, and Zhiran Medical – Named to Rongzhong’s 2025-2026 China Power50 Future Unicorn List

May 26, 2026 21:43 CST Updated 21:43

SANEGENEBIO

Small Nucleic Acid Drug Developer

BCIFlex

Invasive High-Throughput Ultra-Thin Flexible Brain-Computer Interface System Developer

Click the "blue text" above to follow for more updates.

Recently, the Finetop 2025-2026 China Power50 Enterprise List was officially released, with three portfolio companies of YuanSheng Capital—SANEGENEBIO, Excalipoint Therapeutics, and BCIFlex—being honored as “Top 50 Future Unicorns in China”.

# About SANEGENEBIO

SANEGENEBIO is a globally integrated, clinical-stage biotechnology company focused on the development of RNAi therapeutics. Leveraging its proprietary GalNAc liver delivery platform and the industry-leading LEAD™ (Ligand and Enhancer Assisted Delivery) extrahepatic delivery platform, the company is committed to addressing significant unmet clinical needs in obesity, cardiometabolic diseases, and immune-mediated disorders. Founded in 2021 and led by a pioneering team with deep expertise in the RNAi field, SANEGENEBIO operates R&D centers in Suzhou and Shanghai, China, and Boston, USA, and is backed by prominent venture capital investors. The LEAD™ platform enables the highly efficient and specific delivery of siRNA to extrahepatic tissues, including adipose tissue, muscle, immune cells, and the central nervous system, achieving potent, safe, and durable silencing of disease-causing genes while substantially reducing dosing frequency. SANEGENEBIO has established a rapidly expanding pipeline of investigational therapeutics, currently comprising four clinical-stage candidates (one in Phase II and three in Phase I) alongside multiple preclinical programs. Guided by a clear vision, we are dedicated to developing innovative therapies with “Best-in-Class” and “First-in-Class” potential, advancing RNAi therapeutics to become the standard of care across a broad spectrum of diseases, and delivering next-generation transformative treatment options to patients worldwide. For more information, please visit the official SANEGENEBIO website: www.sanegenebio.com

About Excalipoint Therapeutics

Excalipoint Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation innovative T-cell engager (TCE) therapies to address unmet medical needs worldwide. Anchored by its proprietary T-cell therapy technologies, including the TOPAbody platform, T-cell immune shield platform, and TCE prodrug platform, the company focuses on developing novel, differentiated T-cell therapies with strong clinical potential to overcome the technical barriers of existing treatments. Its pipeline encompasses six drug candidates across oncology and immunology, with its lead product, EXP011 (CTM012), currently in Phase I/II clinical trials for solid tumors. For more information, please visit the company’s official website: www.excalipoint.com.

About BCIFlex

Founded in 2022, BCIFlex is an innovative medical device company established by a team of globally leading scientists in advanced materials, micro/nano manufacturing, artificial intelligence, and neuroscience, alongside a highly experienced corporate management team. The company is dedicated to developing a next-generation high-throughput flexible brain-computer interface (BCI) platform based on invasive flexible electrodes. Since its inception over two years ago, BCIFlex has been granted more than 30 domestic and international patents, covering core technological domains in brain-computer interfaces.

END

About Genesis Capital

Genesis CapitalOriza Ventures is a venture capital firm focused on early- and growth-stage investments in the healthcare sector. Headquartered in Suzhou BioBAY with a global reach, we have invested in over 200 outstanding life and health companies across four core areas: novel drug development, medical devices, in vitro diagnostics (IVD) and precision medicine, and future healthcare technologies. These investments have yielded substantial returns, with 21 portfolio companies successfully listed on major capital markets such as the Hong Kong Stock Exchange (HKEX) and the Science and Technology Innovation Board (STAR Market). Oriza Ventures has been consistently ranked among the Top 10 venture capital funds and recognized as one of the most active healthcare investment institutions in China. Backed by seasoned professional investors and a world-class scientific advisory team, we bring extensive experience in biopharmaceutical entrepreneurship, venture capital, and corporate operations. Guided by professionalism, focused dedication, and robust industry resources, we are committed to becoming one of the most successful healthcare venture capital funds in China.